- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 19,078
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, IL2
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Interventions
- Aldesleukin, gp100 Antigen, Montanide ISA 51 VG, Quality-of-Life Assessment, Questionnaire Administration, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Riverside, California + 15 more
- Conditions
- Breast Ductal Carcinoma In Situ
- Interventions
- Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
- Other · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- MK-3795, Nivolumab, Cabozantinib, Bezlutifan
- Drug
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Abuse Potential
- Interventions
- Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Drug
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- HIV Infections, Peripheral Nervous System Disease
- Interventions
- Peptide T
- Drug
- Lead sponsor
- Advanced Peptides
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Miami, Florida • New York, New York
- Conditions
- Autistic Disorder
- Interventions
- N-Acetyl Cysteine, Placebo - sugar pill
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
- Interventions
- Anakinra
- Drug
- Lead sponsor
- Andrea Vambutas
- Other
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Covid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation
- Interventions
- SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
- Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
- Interventions
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Drug
- Lead sponsor
- Perspective Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
- Conditions
- Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
- Interventions
- LP-300, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Lantern Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Fountain Valley, California • Los Alamitos, California + 3 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Bevacizumab (avastin), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Antioch, California • Los Angeles, California + 39 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 58
- States / cities
- Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
- Conditions
- Alcoholic Cirrhosis
- Interventions
- Placebo, SAMe 400 mg tablet
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Indianapolis, Indiana
- Conditions
- Metastatic Melanoma
- Interventions
- MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
- Interventions
- PF-07284890, Binimetinib, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Orlando, Florida + 23 more
- Conditions
- C. Acnes, Phototherapy, Postoperative Infection, Arthroscopic Rotator Cuff Repair, Shoulder Surgery
- Interventions
- Skin Biopsy, 5 Aminolevulinic Acid + Phototherapy
- Procedure · Drug
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hodgkin Disease
- Interventions
- Nivolumab, brentuximab vedotin, bendamustine
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
- Conditions
- Stroke
- Interventions
- autologous bone marrow mononuclear cell transfusion, marrow stromal cells, placebo
- Biological · Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Hemophilia
- Interventions
- Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
- Biological
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 27
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more